1. Scrip
  2. >>Therapy Areas

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

 
• By Brenda Sandburg

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Digital illustration of Cancer cell in colour background

As Pfizer Inc. continues to grow its oncology business, it's pushing both new molecules and expanding the indications of its approved drugs.

Andy Schmeltz, global president of Pfizer Oncology, described the company's strategy as a three-pronged approach at a May 15 press...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas